Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells

American Journal of Hematology

Volumn 86, Issue 12, 2011, Pages 967-973

  Katodritou, Eirini ^a,b   Terpos, Evangelos ^c   North, Janet ^a   Kottaridis, Panagiotis ^a   Verrou, Evgenia ^b   Gastari, Vasiliki ^b   Chadjiaggelidou, Christina ^b   Sivakumaran, Shivajanani ^a   Jide Banwo, Samuel ^a   Tsirogianni, Maria ^a   Kapetanos, Dimitrios ^b   Zervas, Konstantinos ^b   Lowdell, Mark W ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; SYNDECAN 1;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; PLASMA CELL; PRIORITY JOURNAL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BONE MARROW; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DEXAMETHASONE; DISEASE PROGRESSION; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; SYNDECAN-1; TUMOR CELLS, CULTURED;

EID: 81355127553     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22163     Document Type: Article

References (32)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Eng J Med 2004; 351: 1860-1873.
2. Kastritis E, Symeonidis A, Zervas K, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152-1157.
3. Reece D. Management of multiple myeloma: The changing landscape. Blood Rev 2007; 21: 301-314.
4. Gahrton G. Progress in hematopoietic stem cell transplantation in multiple myeloma. Curr Opin Hematol 2005; 12: 463-470.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
6. Quach H, Ritchie D, Stewart AK, et al. Mechanisms of action of immunomodulatory drugs (IMiDs) in multiple myeloma. Leukemia 2010; 24: 22-32.
7. Patil S, Scwarer T. Natural killer cells-New understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation. Int Med 2009; 39: 639-647.
8. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225-274.
9. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006; 214: 73-91.
10. Porrata LF, Gastineau DA, Padley D, et al. Reinfused autologous graft natural kliier cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymph 2003; 44: 997-1000.
11. Lowdell MW, Ray N, Craston R, et al. The in vitro detection of antileukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transpl 1997; 19: 891-897.
12. Lowdell MW, Craston R, Samuel D, et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells anti-leukemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukemia. Br J Haematol 2002; 117: 821-827.
13. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87: 1196-1198.
14. Szmania S, Balasa B, Malaviarachchi P, et al. CS1 is expressed on myeloma cells from early stage, late stage, and drug-treated multiple myeloma patients, and is selectively targeted by the huluc63 antibody. Blood 2006; 108: 660a.
15. Frohn C, Hoppner M, Schlenke P, et al. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002; 119: 660-664.
16. Alici E, Sutlu T, Bjorkstrand B, et al. Autologous anti-tumor activity by NK expanded from myeloma patients using GMP-compliant components. Blood 2008; 111: 3155-3162.
17. Shi J, Tricot G, Szmania S, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol 2008; 143: 641-653.
18. North J, Bakhsh I, Marden C, et al. Tumor-primed natural killer cells lyse NK-resistant tumor targets: Evidence of two-stage process in resting NK cell activation. J Immunol 2007; 178: 85-94.
19. Durie BGM, Haroussaeu JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
20. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: Current insights and future prospective. J Int Med 2009; 266: 154-181.
21. Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKGD. Immunology 2007; 121: 439-447.
22. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 351-358.
23. Fauriat C, Mallet F, Olive D, Costello RT. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 2006; 20: 732-733.
24. El-Sherbiny YM, Meade JL, Holmes TD, et al. The requirement of DNAM-1, NKG2D, and NKp46 in the natural killer-mediated killing of myeloma cells. Cancer Res 2007; 67: 8444-8449.
25. Lehmann C, Zeis M, Schmitz C, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2001; 96: 594-600.
26. Avet-Loiseau H, Attal M, Moreau F, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroup Francophone du Myelome. Blood 2007; 109: 3489-3495.
27. Jarahian M, Watzl C, Issa Y, et al. Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. Int J Cancer 2007; 120: 2625-2634.
28. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killercytotoxicity in multiple myeloma. Blood 2001; 98: 210-216.
29. Callewaert DM, Moudgil VK, Radcliff G, Waite R. Hormone specific regulation of natural killer cells by cortisol. Direct inactivation of the cytotoxic function of cloned human NK cells without an effect on cellular proliferation. FEBS Lett 1991; 285: 108-110.
30. Vitale C, Chiossone L, Cantoni C, et al. The corticosteroid-induced inhibitory effect on NK cell function reflects down-regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity. Eur J Immunol 2004; 34: 3028-3038.
31. Zhou J, Olsen S, Moldovan J, et al. Glucocorticoid regulation of natural cytotoxicity: Effects of cortisol on the phenotype and function of a cloned human natural killer cell line. Cell Immunol 1997; 178: 108-116.
32. Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155-167.